RxDoctor Payments Data

Angela Smith

Nurse Practitioner · Tallahassee, FLNPI 1427508217

Payments from drug & device makers

$3,910in general payments, 2019–2025

Across 212 payments — averaging $18.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$378
  • Ardelyx, Inc.$321
  • Medtronic$287
  • Johnson & Johnson$142
  • Braintree Laboratories, Inc.$138
  • plus $1K from 20 others

What the payments were for

  • Food & beverage$3,910100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,910 in reported general payments places this provider in the 90th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$31,486
Medicare patients
193
Services billed
285

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase40$95,237
LinzessLinaclotide51$38,241
ZenpepLipase/Protease/Amylase16$24,125
Mesalamine18$12,780
Famotidine340$5,124
Balsalazide Disodium18$4,935
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg184$4,300
Ursodiol19$3,684
Omeprazole235$2,561
Mesalamine ErMesalamine33$2,246
Pantoprazole Sodium223$2,209
Esomeprazole Magnesium25$1,137
Colestipol Hcl15$903
Lansoprazole12$484
Sucralfate13$423

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$1,639$133,47891 claims
Aimmune Therapeutics, Inc.Zenpep$60$24,12516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Tallahassee

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →